Kudo, MasatoshiMasatoshiKudoFinn, Richard SRichard SFinnEdeline, JulienJulienEdelineCattan, StéphaneStéphaneCattanOgasawara, SadahisaSadahisaOgasawaraPalmer, Daniel HDaniel HPalmerVerslype, ChrisChrisVerslypeZagonel, VittorinaVittorinaZagonelFartoux, LaetitiaLaetitiaFartouxVogel, ArndtArndtVogelSarker, DebashisDebashisSarkerVerset, GontranGontranVersetChan, Stephen LStephen LChanKnox, JenniferJenniferKnoxDaniele, BrunoBrunoDanieleYau, ThomasThomasYauGurary, Ellen BEllen BGurarySiegel, Abby BAbby BSiegelWang, AnranAnranWangANN-LII CHENGZhu, Andrew XAndrew XZhu2023-01-122023-01-122022-050959-8049https://scholars.lib.ntu.edu.tw/handle/123456789/627198Pembrolizumab, a PD-1 inhibitor, demonstrated anti-tumour activity and tolerability in patients treated with sorafenib and with advanced hepatocellular carcinoma in KEYNOTE-224. Longer-term efficacy and safety after ∼2.5 years of additional follow-up are reported.enAdvanced hepatocellular carcinoma; Anti-PD-1; Long-term treatment; Pembrolizumab[SDGs]SDG3journal article10.1016/j.ejca.2022.02.009353644212-s2.0-85127171092WOS:000793360500001https://api.elsevier.com/content/abstract/scopus_id/85127171092